Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN 5% vs TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is a parenteral nutrition solution that provides a source of amino acids, electrolytes, and calories. The amino acids serve as substrates for protein synthesis and energy metabolism, replenishing nitrogen balance and supporting tissue repair and growth.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion. Individualized based on protein and electrolyte requirements. Typical adult dose: 500-2000 mL/day of 8.5% amino acid solution, infused at 60-125 mL/hour.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Amino acids have short half-lives (minutes to hours) due to rapid metabolism; no single terminal half-life for mixture. Electrolytes have distribution half-lives of minutes.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Renal: Amino acids are extensively reabsorbed; excess nitrogen is excreted as urea (renal, majority). Electrolytes are excreted renally with reabsorption regulation. Biliary/fecal: Negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution